Investment Analysts’ Weekly Ratings Updates for Immunome (IMNM)

A number of firms have modified their ratings and price targets on shares of Immunome (NASDAQ: IMNM) recently:

• 4/2/2025 – Immunome is now covered by analysts at Lake Street Capital. They set a “buy” rating and a $23.00 price target on the stock.
• 3/20/2025 – Immunome had its “overweight” rating reaffirmed by analysts at Stephens. They now have a $30.00 price target on the stock.
• 3/20/2025 – Immunome had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.
• 3/20/2025 – Immunome had its price target lowered by analysts at Guggenheim from $35.00 to $25.00. They now have a “buy” rating on the stock.
• 3/11/2025 – Immunome is now covered by analysts at Lifesci Capital. They set an “outperform” rating and a $20.00 price target on the stock.
• 3/10/2025 – Immunome had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.

Immunome Stock Performance

IMNM traded down $0.23 during trading on Monday, hitting $5.71. 335,779 shares of the stock were exchanged, compared to its average volume of 881,573. The firm has a 50 day simple moving average of $9.13 and a 200 day simple moving average of $10.96. The firm has a market cap of $496.06 million, a price-to-earnings ratio of -0.70 and a beta of 2.05. Immunome, Inc. has a 1 year low of $5.40 and a 1 year high of $21.72.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The firm had revenue of $2.74 million for the quarter, compared to analyst estimates of $3.07 million. As a group, equities analysts anticipate that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Insider Activity at Immunome

In related news, CTO Philip Tsai acquired 12,300 shares of the firm’s stock in a transaction dated Monday, March 24th. The stock was acquired at an average price of $8.42 per share, for a total transaction of $103,566.00. Following the purchase, the chief technology officer now owns 33,300 shares of the company’s stock, valued at $280,386. This represents a 58.57 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Clay B. Siegall acquired 150,000 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was acquired at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the acquisition, the chief executive officer now owns 669,636 shares in the company, valued at approximately $5,189,679. The trade was a 28.87 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 306,400 shares of company stock worth $2,322,995. Corporate insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Immunome

Large investors have recently modified their holdings of the company. Enavate Sciences GP LLC acquired a new stake in Immunome during the 4th quarter worth $36,939,000. Price T Rowe Associates Inc. MD increased its position in Immunome by 12.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,282,754 shares of the company’s stock valued at $24,243,000 after acquiring an additional 246,447 shares during the period. Geode Capital Management LLC lifted its position in Immunome by 1.8% during the 4th quarter. Geode Capital Management LLC now owns 1,228,851 shares of the company’s stock worth $13,054,000 after acquiring an additional 21,396 shares during the period. Woodline Partners LP increased its holdings in shares of Immunome by 6.1% in the fourth quarter. Woodline Partners LP now owns 980,925 shares of the company’s stock valued at $10,417,000 after purchasing an additional 56,533 shares during the period. Finally, Point72 Asset Management L.P. increased its stake in Immunome by 46.3% in the 4th quarter. Point72 Asset Management L.P. now owns 688,790 shares of the company’s stock valued at $7,315,000 after buying an additional 218,143 shares during the period. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.